Paper36964457
Clinical benefit of MAO-B and COMT inhibition in Parkinson's disease: practical considerations.
Regensburger M and 6 others. J Neural Transm (Vienna), 2023. Cited by 56 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Clinical benefit of MAO-B and COMT inhibition in Parkinson's disease: practical considerations. Papers, record 36964457. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36964457
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Clinical benefit of MAO-B and COMT inhibition in Parkinson's disease: practical considerations.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Parkinson Disease | Major topic |
| Humans | |
| Antiparkinson Agents | |
| Monoamine Oxidase | |
| Catechol O-Methyltransferase | |
| Levodopa | |
| Catechol O-Methyltransferase Inhibitors | |
| Monoamine Oxidase Inhibitors |
Source PubMed
References134
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 15,551,331 | Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. | Mov Disord | 2005 | https://conductscience.org/library/papers/15551331 | PubMed |
| 2 | 9,305,320 | Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. The Tolcapone Stable Study Group. | Neurology | 1997 | https://conductscience.org/library/papers/9305320 | PubMed |
| 3 | 10,027,853 | Biochemical and electrophysiological studies on the mechanism of action of PNU-151774E, a novel antiepileptic compound. | J Pharmacol Exp Ther | 1999 | https://conductscience.org/library/papers/10027853 | PubMed |
| 4 | 12,470,183 | A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. | Arch Neurol | 2002 | https://conductscience.org/library/papers/12470183 | PubMed |
| 5 | 30,673,543 | Randomized Delayed-Start Trial of Levodopa in Parkinson's Disease. | N Engl J Med | 2019 | https://conductscience.org/library/papers/30673543 | PubMed |
| 6 | 29,971,495 | Levodopa-induced dyskinesia: clinical features, incidence, and risk factors. | J Neural Transm (Vienna) | 2018 | https://conductscience.org/library/papers/29971495 | PubMed |
| 7 | 24,756,517 | Pharmacological treatment of Parkinson disease: a review. | JAMA | 2014 | https://conductscience.org/library/papers/24756517 | PubMed |
| 8 | 36,346,534 | The XINDI Study: A Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Safinamide as Add-On Therapy to Levodopa in Chinese Patients with Parkinson's Disease with Motor Fluctuations. | CNS Drugs | 2022 | https://conductscience.org/library/papers/36346534 | PubMed |
| 9 | 26,817,533 | Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients. | Mov Disord | 2016 | https://conductscience.org/library/papers/26817533 | PubMed |
| 10 | 35,705,887 | Opicapone as an Add-on to Levodopa in Patients with Parkinson's Disease Without Motor Fluctuations: Rationale and Design of the Phase III, Double-Blind, Randomised, Placebo-Controlled EPSILON Trial. | Neurol Ther | 2022 | https://conductscience.org/library/papers/35705887 | PubMed |
| 11 | 10,803,796 | A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia. | Clin Neuropharmacol | 2000 | https://conductscience.org/library/papers/10803796 | PubMed |
| 12 | 8,988,465 | Pharmacology and neuroprotective properties of rasagiline. | J Neural Transm Suppl | 1996 | https://conductscience.org/library/papers/8988465 | PubMed |
| 13 | 32,446,176 | Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease: A randomized, double-blind, placebo-controlled, phase II/III study. | Parkinsonism Relat Disord | 2020 | https://conductscience.org/library/papers/32446176 | PubMed |
| 14 | 15,590,952 | Levodopa and the progression of Parkinson's disease. | N Engl J Med | 2004 | https://conductscience.org/library/papers/15590952 | PubMed |
| 15 | 22,136,163 | Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial. | Eur J Neurol | 2012 | https://conductscience.org/library/papers/22136163 | PubMed |
| 16 | 15,096,406 | A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. | Arch Neurol | 2004 | https://conductscience.org/library/papers/15096406 | PubMed |
| 17 | 34,554,335 | Safinamide improves sleep and daytime sleepiness in Parkinson's disease: results from the SAFINONMOTOR study. | Neurol Sci | 2022 | https://conductscience.org/library/papers/34554335 | PubMed |
| 18 | 29,167,350 | Safinamide Differentially Modulates In Vivo Glutamate and GABA Release in the Rat Hippocampus and Basal Ganglia. | J Pharmacol Exp Ther | 2018 | https://conductscience.org/library/papers/29167350 | PubMed |
| 19 | 12,211,134 | Management of Parkinson's disease: an evidence-based review. | Mov Disord | 2002 | https://conductscience.org/library/papers/12211134 | PubMed |
| 20 | 28,523,235 | Effects of levodopa/carbidopa intestinal gel versus oral levodopa/carbidopa on B vitamin levels and neuropathy. | Brain Behav | 2017 | https://conductscience.org/library/papers/28523235 | PubMed |
Cited by44
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 56 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,974,025 | Effects of eating behavior patterns and dietary habits on the therapeutic efficacy of Parkinson's disease medications: from phenomena, mechanisms to clinical applications. | Front Nutr | 2026 | https://conductscience.org/library/papers/42974025 | PubMed |
| 42,829,398 | The safety and tolerability of opicapone in elderly Parkinson's disease patients: a real-world, multicenter, retrospective study. | J Neural Transm (Vienna) | 2026 | https://conductscience.org/library/papers/42829398 | PubMed |
| 42,730,819 | German Delphi consensus: COMT inhibitors in the management of wearing-off fluctuations in Parkinson's disease. | J Neural Transm (Vienna) | 2026 | https://conductscience.org/library/papers/42730819 | PubMed |
| 42,679,808 | Carotid body dysfunction contributes to respiratory instability in Rett syndrome. | Curr Biol | 2026 | https://conductscience.org/library/papers/42679808 | PubMed |
| 42,575,718 | Rational Design of Multifunctional Tacrine Derivatives as Candidates for the Treatment of Alzheimer and Parkinson Diseases. | ChemMedChem | 2026 | https://conductscience.org/library/papers/42575718 | PubMed |
| 42,558,392 | Neuroprotective role of Lactiplantibacillus plantarum C10-derived SCFAs: a functional food approach targeting gut-brain-axis disruption in rotenone-induced Parkinson's disease in-vivo in adult zebrafish. | Front Nutr | 2026 | https://conductscience.org/library/papers/42558392 | PubMed |
| 42,356,373 | Curcumin, Coenzyme-Q10, and Bioactive Compounds in Ashwagandha Extract: Multi-Targeting Potential of Co-Administered Natural Health Compounds as Therapeutic and Preventative Interventions in Alzheimer's and Parkinson's Disease Models. | Nutrients | 2026 | https://conductscience.org/library/papers/42356373 | PubMed |
| 42,252,551 | The Use of Statins in Parkinson's and Alzheimer's Disease: A 2021-2025 State-of-the-Art Review of Clinical and Preclinical Evidence. | Pharmacol Res Perspect | 2026 | https://conductscience.org/library/papers/42252551 | PubMed |
| 42,016,531 | Opicapone in Parkinson's patients with motor fluctuations: clinical assessments and patient-reported outcomes from the OPTI-ON study. | Clin Park Relat Disord | 2026 | https://conductscience.org/library/papers/42016531 | PubMed |
| 41,949,708 | Parkinson's disease: pathogenesis and therapeutic strategies. | Mol Biomed | 2026 | https://conductscience.org/library/papers/41949708 | PubMed |
| 41,782,314 | Advanced Parkinson's disease treatment patterns in Italy: results from a multicenter observational study. | Ann Med | 2026 | https://conductscience.org/library/papers/41782314 | PubMed |
| 41,716,552 | Efficacy of MAO-B and COMT inhibitors on quality of life in patients with Parkinson's disease: a Bayesian network meta-analysis. | Front Neurol | 2026 | https://conductscience.org/library/papers/41716552 | PubMed |
| 41,646,181 | Molecular mechanisms of exercise-induced neuroprotection against Parkinson's disease. | Sports Med Health Sci | 2026 | https://conductscience.org/library/papers/41646181 | PubMed |
| 41,516,245 | Neuroprotective and Antioxidant Activity of Newly Synthesized N-Pyrrolyl Hydrazide-Hydrazones in Experimental Models of Neurotoxicity In Vitro and In Vivo. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41516245 | PubMed |
| 41,471,556 | Microwave Imaging for Parkinson's Disease Detection: A Phantom-Based Feasibility Study Using Temperature-Controlled Dielectric Variations. | Sensors (Basel) | 2025 | https://conductscience.org/library/papers/41471556 | PubMed |
| 41,471,108 | Sialic Acid in Neurodegenerative and Psychiatric Disorders: From Molecular Regulation to Targeted Nanocarrier-Based Therapy. | Pharmaceutics | 2025 | https://conductscience.org/library/papers/41471108 | PubMed |
| 41,465,423 | The Effect of Dopaminergic Therapies in Parkinson's Disease on Non-Motor Symptoms. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41465423 | PubMed |
| 41,304,978 | Catharanthus roseus Phytochemicals as Multi-Target Modulators of Disability-Linked Neurodegeneration: Bio-Computational Insights. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/41304978 | PubMed |
| 41,276,723 | Neuroprotective Attributes of Gut-derived Urolithins in Parkinson's Disease. | Mol Neurobiol | 2025 | https://conductscience.org/library/papers/41276723 | PubMed |
| 41,204,267 | Biomimetic nanodelivery system with simultaneous blood-brain barrier-crossing and neuroprotective abilities for anti-parkinsonian therapy. | Chin Med | 2025 | https://conductscience.org/library/papers/41204267 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| COMT | 1,312 | PubTator's text mining | https://conductscience.org/library/genes/1312 | NCBI Gene |
| MAOB | 4,129 | PubTator's text mining | https://conductscience.org/library/genes/4129 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36964457
GET https://conductscience.org/api/papers/v1/36964457/references?page=2